PSA Level Three Months After Radiation Tx May Predict Outcome

Share this content:
PSA Level Three Months After Radiation Tx May Predict Outcome
PSA Level Three Months After Radiation Tx May Predict Outcome

THURSDAY, May 24, 2018 (HealthDay News) -- Prostate-specific antigen (PSA) levels three months after radiotherapy (RT) are strong markers of prostate cancer outcomes for patients with intermediate- and high-risk disease, according to a study published online May 4 in Cancer.

Alex K. Bryant, from University of California at San Diego, and colleagues used Veterans Affairs data to identify 5,783 patients with intermediate-risk or high-risk localized prostate cancer who were diagnosed between 2000 and 2015 and treated with RT and androgen deprivation therapy. Patients were characterized by three-month post-RT PSA values: <0.10 ng/mL, 0.10 to 0.49 ng/mL, and ≥0.50 ng/mL.

The researchers found that a higher three-month PSA level was strongly associated with biochemical progression-free survival (bPFS), prostate cancer-specific survival (PCSS), and overall survival (OS). Greater hazards were noted for patients with a three-month PSA level ≥0.50 ng/mL versus a three-month PSA value <0.10 ng/mL (hazard ratios: bPFS, 5.23; PCSS, 3.97; and OS, 1.50 [P < 0.001 for all]). Greater hazards were also seen for patients with a three-month PSA value of 0.10 to 0.49 ng/mL (hazard ratios: bPFS, 2.41 [P < 0.001]; PCSS, 2.29 [P < 0.001]; and OS, 1.21 [P = 0.003]). When analyzed separately, three-month PSA levels were found to be predictive of OS in the high-risk group (P < 0.001) but not the intermediate-risk group (P = 0.21).

"The three-month PSA measurement may augment clinical decision making and holds promise as a potential surrogate end point in clinical trials," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

NIH Panel Will No Longer Review Gene Therapy Experiments

NIH Panel Will No Longer Review Gene Therapy ...

FDA will now assess gene therapy experiments and products as it does with other treatments, drugs

Doctors Remove Contact Lens Embedded in Eyelid for Years

Doctors Remove Contact Lens Embedded in Eyelid for ...

Lens was encapsulated within the upper eyelid soft tissue since childhood eye trauma

CDC: Brucellosis in Dogs Remains a Public Health Risk

CDC: Brucellosis in Dogs Remains a Public Health ...

Infection is under-recognized, may remain a threat without stronger intervention measures

is free, fast, and customized just for you!




Already a member?

Sign In Now »